Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    White Sox Relief Pitcher Liam Hendriks Shares Non-Hodgkin’s Lymphoma (NHL) Diagnosis
    source: pixabay.com

    White Sox Relief Pitcher Liam Hendriks Shares Non-Hodgkin’s Lymphoma (NHL) Diagnosis

      Known as “Slydah,” Chicago White Sox relief pitcher (RP) Liam Hendriks has done amazing things on the field. In September/October 2021, Hendriks was named the American League Reliever of…

    Continue Reading White Sox Relief Pitcher Liam Hendriks Shares Non-Hodgkin’s Lymphoma (NHL) Diagnosis
    Could SGSH Enzyme Replacement Therapy Benefit Children with MPS III-A?
    Source: Pixabay.com

    Could SGSH Enzyme Replacement Therapy Benefit Children with MPS III-A?

      Enzyme replacement therapy (ERT) has been explored as a potential therapeutic option for mucopolysaccharidosis type III A (MPS III-A or Sanfilippo syndrome type A). However, these solutions have not…

    Continue Reading Could SGSH Enzyme Replacement Therapy Benefit Children with MPS III-A?
    Anti-Hyperglycemic Medication Increases MS Risk in Adults with Type 2 Diabetes
    source: pixabay.com

    Anti-Hyperglycemic Medication Increases MS Risk in Adults with Type 2 Diabetes

      Over the past few decades, research has shown a potential connection between metabolic disorders and multiple sclerosis (MS). While this connection has been made, anti-hyperglycemic medications (often used to…

    Continue Reading Anti-Hyperglycemic Medication Increases MS Risk in Adults with Type 2 Diabetes
    Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff
    Source: Pixabay.com

    Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff

    There are limited therapeutic options for people living with autosomal dominant polycystic kidney disease (ADPKD); currently, the only real standards-of-care include dialysis and kidney transplantation. When discussing the therapeutic landscape,…

    Continue Reading Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff